Curtana Pharmaceuticals is developing first-in-class, small molecule therapeutics that are highly specific for cancer stem cells in the central nervous system (CNS) for the treatment of glioblastoma (GBM) and other brain cancers. The company has identified a number of promising compounds that have demonstrated target-selective anti-GBM potency in a variety of in vitro assays and in an in vivo model of GBM.
GBM is the most common and deadliest of the malignant primary brain tumors in adults. Standard treatment is surgery, followed by radiation therapy and chemotherapy with temozolomide. There remains significant unmet clinical need in the GBM market as the median survival is less than 15 months.
In the U.S., there are approximately 10,000 new cases of GBM per year, making it an orphan indication.
The U.S. market for the treatment of GBM and other malignant gliomas is valued at $380 million per year and the world-wide market is valued at approximately $1 billion.